You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Details for Patent: 7,994,220

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,994,220 protect, and when does it expire?

Patent 7,994,220 protects SAVELLA and is included in one NDA.

This patent has thirty-three patent family members in twenty-three countries.

Summary for Patent: 7,994,220

Patent landscape, scope, and claims:

Title:	Milnacipran for the long-term treatment of fibromyalgia syndrome
Abstract:	The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.
Inventor(s):	Rao; Srinivas G. (Encinitas, CA), Gendreau; Michael (Poway, CA), Kranzler; Jay D. (La Jolla, CA)
Assignee:	Cypress Bioscience, Inc. (San Diego, CA)
Application Number:	11/535,237
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,994,220
Patent Claim Types: see list of patent claims	Use; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 7,994,220

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-001	Jan 14, 2009	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe				MANAGEMENT OF FIBROMYALGIA	⤷ Subscribe
Abbvie	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-002	Jan 14, 2009	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe				MANAGEMENT OF FIBROMYALGIA	⤷ Subscribe
Abbvie	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-003	Jan 14, 2009	AB	RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				MANAGEMENT OF FIBROMYALGIA	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 7,994,220

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006294645	⤷ Subscribe
Brazil	PI0617541	⤷ Subscribe
Canada	2624018	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.